Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp59 | Acromegaly and GH | ECE2019

Effects of pegvisomant and pasireotide LAR on incidence of vertebral fractures in patients with acromegaly resistant to treatment with first-line somatostatin analogs

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Bima Chiara , Frara Stefano , Mirra Federica , Donfrancesco Federico , Fleseriu Cara Maria , Fleseriu Maria , Giustina Andrea , Laura De Marinis , Pontecorvi Alfredo

Purpose: Osteopathy is an emerging complication of acromegaly characterized by increased bone turnover, deterioration in bone microarchitecture and high risk of vertebral fractures (VFs). In somatostatin analog (SSA)-resistant patients (pts), Pegvisomant (PegV) and Pasireotide LAR (Pasi) are used for acromegaly treatment, but their effect on skeletal health is still not defined.Methods: In a longitudinal international multicenter study, we evaluated inci...

ea0056p875 | Pituitary - Clinical | ECE2018

Efficacy of pasireotide lar in first line somatostatin analogue resistant acromegaly patients: experience from a large and single centre Italian cohort

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Tartaglione Tommaso , Bima Chiara , Piacentini Serena , Mirra Federica , Donfrancesco Federico , Lauretti Liverana , Anile Carmelo , Pontecorvi Alfredo , De Marinis Laura

Introduction: Pasireotide Lar is a new generation long-acting somatostatin multireceptor ligand, approved for the treatment of first line somatostatin analogue resistant patients. We aimed to review Pasireotide Lar efficacy data, in our series of patients affected by aggressive acromegaly.Patients: A retrospective longitudinal study was conducted on patients with aggressive acromegaly, resistant to first-line somatostatin analogues (SSA) and on treatment...

ea0070aep662 | Pituitary and Neuroendocrinology | ECE2020

Predictors of response to medical therapy with pegvisomant and pasireotide lar in SRLs-resistant acromegaly

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Mirra Federica , Donfrancesco Federico , Maya Fleseriu Cara , Lauretti Liveraba , Anile Carmelo , Gessi Marco , Rindi Guido , Pontecorvi Alfredo , Fleseriu Maria , Giustina Andrea , De Marinis Laura

Background: Pegvisomant(PegV) and Pasireotide LAR(Pasi) are commonly used in acromegaly patients resistant to first-generation SRLs. Predictors of response to therapy with PegV and Pasi in this subset of patients are still unclear. These findings may be useful in choosing the most appropriate therapeutic option for the personalized treatment of patients affected by more aggressive disease. We aimed to identify individual predictors of responses.Methods: ...